Frédéric Vanhoutte

SGS (Belgium) — Belgium

Medicine · Health Sciences

16h-index1.3kcitations43works4.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(10), Rheumatoid Arthritis Research and Therapies(9), Systemic Lupus Erythematosus Research(4), Cytokine Signaling Pathways and Interactions(4), Inflammatory Bowel Disease(3)

Publications43 total

Safety and Pharmacokinetics of <scp>MK</scp> ‐8527 in Adults Without <scp>HIV</scp>
Clinical and Translational Science·2025· 1 citedOpen Access
Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant
Pulmonary Pharmacology & Therapeutics·2024· 5 citedOpen Access
Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first‐in‐human phase I study
Clinical and Translational Science·2024· 8 citedOpen Access
Towards minimizing carbon footprint of triple fixed dose MDIs for severe asthmatic patients: relative lung bioavailability and total systemic exposure of a high dose formulation of BDP/FF/GB with novel propellant
2023
† Pharmacokinetics of Mibavademab in Healthy Participants: Results from a Randomized, Phase 1, Two-Part, First-in-Human Study
Journal of clinical lipidology·2023
Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers
Clinical Infectious Diseases·2023· 34 citedOpen Access
Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial
EBioMedicine·2022· 25 citedOpen Access
A Randomized, Double‐Blind, Placebo‐Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX‐02 in Healthy Subjects
Clinical Pharmacology in Drug Development·2021· 34 citedOpen Access
Issue Information
The Journal of Clinical Pharmacology·2020Open Access
Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti‐Activin A): Results From a First‐in‐Human Phase 1 Study
The Journal of Clinical Pharmacology·2020· 52 citedOpen Access
Randomized study of the effect of gadopiclenol, a new gadolinium‐based contrast agent, on the QTc interval in healthy subjects
British Journal of Clinical Pharmacology·2020· 15 citedOpen Access
Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis
Antimicrobial Agents and Chemotherapy·2019· 40 citedOpen Access
Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers
Clinical Pharmacology in Drug Development·2019· 69 citedOpen Access
Sputum induction for assessment of biomarkers in early respiratory drug development
International Journal of Clinical Pharmacology and Therapeutics·2018
ADAMTS-5 inhibitor GLPG1972, a potential new treatment in osteoarthritis, shows favorable safety, pharmacokinetics and pharmacodynamics in healthy subjects
Osteoarthritis and Cartilage·2018· 11 citedOpen Access
AT-527, a pan-genotypic purine nucleotideprodrug, exhibits potent antiviral activity in subjects with chronic hepatitis C
Journal of Hepatology·2018· 2 cited
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
Arthritis & Rheumatology·2017· 75 citedOpen Access
P610 Efficacy and safety of GLPG1205, a GPR84 antagonist, in ulcerative colitis: multi-centre proof-of-concept study
Journal of Crohn s and Colitis·2017· 16 citedOpen Access
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
Annals of the Rheumatic Diseases·2016· 226 citedOpen Access
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
Annals of the Rheumatic Diseases·2016· 227 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Annegret Van der Aa(11), Florence Namour(10), Johan Beetens(9), Piet Wigerinck(7), Gerben van ‘t Klooster(6), Sonia Dupont(5), René Westhovens(4), Minodora Mazur(4), Maria Greenwald(4), Chantal Tasset(4), Pille Harrison(4), René Galien(4), Yuhuan Wang(4), Lien Gheyle(4), Mykola Stanislavchuk(3), Tim Van Kaem(3), An Sha Zhao(3), John D. Davis(3), Julie Desrivot(3), F. Namour(3)